Tildacerfont is a potent and orally active corticotropin-releasing factor type 1 (CRF1) receptor antagonist. It effectively reduces levels of adrenocorticotropic hormone (ACTH) and adrenal androgens, demonstrating a favorable safety profile. Tildacerfont is being investigated for the treatment of congenital adrenal hyperplasia (CAH) and holds promise for research into disorders of the hypothalamic-pituitary-adrenal (HPA) axis.
Tildacerfont is a potent and orally active corticotropin-releasing factor type 1 (CRF1) receptor antagonist. It effectively reduces levels of adrenocorticotropic hormone (ACTH) and adrenal androgens, demonstrating a favorable safety profile. Tildacerfont is being investigated for the treatment of congenital adrenal hyperplasia (CAH) and holds promise for research into disorders of the hypothalamic-pituitary-adrenal (HPA) axis.
Store lyophilized at -20ºC, keep desiccated. In lyophilized form, the chemical is stable for 36 months. In solution, store at -20ºC and use within 1 months to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.
This calculator helps you calculate mass of compound based on solution concentration, volume and molecular weight in a specific solution using the formula:
